NOTRELOAD AI
  • NOTRELOAD AI
  • Invest ↗
  • myNOTRELOAD (BETA)
  • XY Feed
  • 24-HOUR Pass →
Sign in Subscribe

Wall Street Starts Coverage on PLSE and ENGN: What You Need to Know

Mizuho and Jefferies initiate coverage on Pulse Biosciences and enGene, highlighting growth potential, strong clinical data, and upcoming catalysts in biotech.

Wall Street Starts Coverage on PLSE and ENGN: What You Need to Know
Credit: Pulse Biosciences
Already have an account? Sign in.
01/30/2026 · 9:54 AM
ENGN
/ Don’t stop at just one post.

Related↓

enGene Upgraded to Strong Buy on Promising Bladder Cancer Data
11/11/2025 · 9:46 AM

enGene Upgraded to Strong Buy on Promising Bladder Cancer Data

Raymond James upgrades enGene to Strong Buy with $27 target as detalimogene shows 62% complete response rate in bladder cancer trial with excellent tolerability.

/ Subscriber only
/ Read more

Feed↓

Nike Shakes Up Innovation Team Again as Stock Hits 10-Year Low
04/10/2026 · 3:52 PM

Nike Shakes Up Innovation Team Again as Stock Hits 10-Year Low

Nike innovation chief leaves after less than a year amid falling sales, China struggles, and faster rivals; company reshuffles leadership.

/ Subscriber only
Commvault Explores Sale After Takeover Interest from Thoma Bravo
04/10/2026 · 1:23 PM

Commvault Explores Sale After Takeover Interest from Thoma Bravo

Commvault may be sold as buyers show interest. Stock down on AI fears but revenue growing; Thoma Bravo among potential bidders.

/ Subscriber only
FDA Rejects Replimune’s Skin Cancer Drug for the Second Time
Featured/ 04/10/2026 · 12:06 PM

FDA Rejects Replimune’s Skin Cancer Drug for the Second Time

FDA again rejects Replimune’s skin cancer drug RP1, saying studies don’t prove it works; shares halted, setback for company.

/ Subscriber only
  • UP↑
  • Terms/Privacy
  • Sign up
  • Sign in
  • Discord
  • X
  • Bluesky
  • Telegram
  • Reach out →
  • Invest ↗
  • NOTRELOAD AI
DON'T FALL BEHIND. ©2026
Email address Subscribe